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Abstract 
Malaria is a worldwide public health burden that has been reported by the World Health 
Organization (WHO) to cause roughly 219 million cases of disease in 2010 with an 
estimated 660,000 deaths (2013).  In the Caribbean nation of Haiti, malaria remains 
endemic.  Confirmed malaria cases reported in Haiti increased from 10,802 in 2004 to 
49,535 in 2009 (WHO, 2009a).  Currently, P. falciparum is the predominant species to 
cause disease in Haiti, and unfortunately, the same species that is most likely to cause 
severe malaria; responsible for most malarial deaths globally (WHO, 2009a).  
Fortunately though, if treated early, a readily available drug, chloroquine phosphate, can 
effectively treat this strain.  However, although chloroquine has proved to be an 
effective cure for nearly 40 years, the emergence and spread of chloroquine-resistant 
parasites are occurring both worldwide and in Haiti.  The impact of these resistant cases 
on this already impoverished nation could be devastating.  This document will outline 
three recommendations to serve as practical public health strategies on how to lower 
the risks associated with malaria, thus combating a potential outbreak of chloroquine-
resistant malaria (CRM) in Haiti.   
 
 
 
 
 
 3 
 
Introduction 
 Once the leading cause of death due to infectious agents, malaria is now ranked 
third after HIV and tuberculosis (Damodaran, 2013). Current World Health Organization 
estimates state that in 2010 there were roughly 219 million cases of disease with an 
estimated 660,000 deaths.  These numbers are down from previous WHO estimates in 
2008 of 243 million cases with 863,000 deaths. WHO places 3.3 billion people, i.e., 50% 
of the world population at risk of contracting malaria, with 2.1 billion at a low risk and 1.2 
billion at a high risk (WHO, 2013b).  
  
 The goal of this document will be to provide recommendations for dealing with 
CRM in Haiti on the micro-level.  Because dealing with the country of Haiti at this time is 
such a difficult and convoluted situation, the recommendations will focus on the micro-
level.   
 
 Prior to the recommendations, an overview of malaria will be discussed with 
specific information on epidemiology, vectors, diagnosis, medicines available, and drug 
resistance.  When reviewing malaria, a particular focus will be on the strain Plasmodium 
falciparum due to its drug resistance and the subsequent potential impact that this might 
play.   
 
Malaria Overview 
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 Malaria is a serious febrile illness that is caused by a protozoan parasite.  This 
microorganism belongs to the genus Plasmodium.  The Plasmodium parasite infects 
humans through the bites of infected mosquitoes, also known as “malaria vectors”.   
 According to the World Health Organization (WHO), there are four known 
Plasmodium species that cause infections in humans: 
 
• Plasmodium falciparum 
• Plasmodium vivax 
• Plasmodium malariae 
• Plasmodium ovale 
  
 P. falciparum and P. vivax are the two most common species; responsible for 
95% of cases reported worldwide.  P. falciparum is known to be the most deadly (2013).  
 
 Transmission of malaria is caused exclusively through the bite of the female 
Anopheles mosquito.  The lifecycle of the Plasmodium parasite is quite complex and 
needs 10-18 days to infect its mosquito host in order to be transmitted to the human 
host.  Malaria can cause an acute febrile illness.  Symptoms generally begin 10 days to 
4 weeks after infection and can range from absent or very mild to severe which can 
include death (WHO, 2013).  The risk of malaria does not seem to be evenly distributed 
throughout the year. Most cases of malaria occur between November and January. 
 
 Malaria symptoms are categorized as uncomplicated or severe.  An 
uncomplicated, classic attack lasts 6-10 hours and can consist of a cold stage 
(shivering); a hot stage (fever, headaches, vomiting); and a sweating stage (sweats, 
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tiredness).  A classical attack repeats itself every second or third day depending on the 
Plasmodium species.  This uncomplicated, classic attack can look very similar to 
influenza.   
 
 Severe malaria occurs when serious organ failure occurs or because of 
abnormalities in the patient’s blood.  Some of the problems of severe malaria include: 
cerebral malaria, severe anemia, hemoglobinuria, acute respiratory distress syndrome, 
abnormalities in blood coagulation, low blood pressure, acute kidney failure, 
hyperparasitemia, metabolic acidosis, or hypoglycemia (WHO, 2013).   
 
Surveillance Methods 
 Surveillance is necessary in order to determine the severity of a disease and to 
meet elimination objectives. Regarding malaria, surveillance is performed for four major 
reasons: 
1. The need for rapid detection of existing, new or reintroduced disease 
2. The identifications of periods of low transmission when the disease could be 
responding to an elimination effort 
3. Understanding of trends in incidence and prevalence or shifts in disease 
4. The detection of resistance of disease to conventional forms of treatment.   
  
 Currently there are two surveillance tools that are used for malaria detection; 
microscopy and rapid diagnostic test (RDT).  The long-term choice of which of these 
diagnostic tools to use; microscopy, RDT, or a combination of both, will depend on 
multiple factors. These factors include:  
• Skills available of health care personnel 
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• Patient case-load 
• Funds allocated 
• Availability/use of microscopy for other diseases (Wongsrichanalai, 2007) 
  
 In the United States, both microscopy and RDTs are recommended, and at 
minimum, either test should be available at health-care facilities for malaria diagnosis.  
In Haiti, having a similar recommendation of implementing both RDTs and microscopy 
would be ideal, however this is not always practical or feasible.  In many instances, 
neither test is available and presumptive diagnosis is used.  A presumptive diagnosis 
identifies the likely condition a patient has, whereas a surveillance tool would be used to 
confirm the presence of the condition.  
  
 Presumptive diagnosis and treatment of uncomplicated malaria continues to be 
common in many developing countries, including Haiti, even despite well-known 
problems with this strategy. Clinical symptoms of uncomplicated malaria are nonspecific 
and overlap with several other diseases; as such, diagnosing malaria based on 
symptoms alone leads to substantial over diagnosis of malaria.  Massive overtreatment 
with antimalarials is likely to be unsustainable in areas where drug resistance occurs. 
 
 Current World Health Organization (WHO) guidelines on malaria case 
management recommend parasitological confirmation before treatment with an 
antimalarial. The gold standard has for many years been microscopy. However, unless 
the laboratory technicians are well trained and the equipment well maintained, the 
accuracy of microscopy can be low under field conditions.  Rapid diagnostic tests 
(RDTs) for malaria require limited training and have been found to perform well in 
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certain situations. 
 
 A major potential barrier to the use of surveillance tools for malaria is the cost of 
the tests. However, improved targeting of antimalarial treatment to parasite-positive 
patients has been found to result in substantial cost savings of antimalarial drugs, 
sometimes even enough to also cover the additional costs of the testing. 
 
Rates of Disease 
 The most recent data released by the World Malaria Report 2012 summarizes 
data received from 104 malaria-endemic countries and territories for 2011. Ninety-nine 
of these countries had on-going malaria transmission.  In this report, the WHO 
estimates in 2010 there were about 219 million cases of malaria worldwide. A total of 
106 endemic areas were identified with Africa was the most affected continent. Africa 
has approximately 90% of all malaria deaths occurring there (2012). 
 
 Haiti has always been particularly vulnerable to malaria.  However, the Haitian 
earthquake on January 12, 2010, which killed an estimated quarter of a million people 
and displaced over a tenth of the Haitian population, has turned the malaria situation 
from a proverbial festering sore to full-blown sepsis.   Whereas in most places in the 
world, malaria is on the decline, confirmed malaria cases reported in Haiti increased.  
The most recent WHO report states that there were a total of10,802 in 2004.  In 2009 
though, this number ballooned up to 49,535 (2009b).   
 
 This dramatic increase is quite alarming.  What is also alarming is that P. 
falciparum is the predominant species to cause disease in Haiti.  And unfortunately, this 
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is the same species that is most likely to cause severe malaria and death.   
 
Current Malaria Treatments 
 Malaria can be a treatable disease with the correct anti-parasitic medicine.  The 
most readily available and least expensive of these medicines is called chloroquine.  
However, drug resistance can occur to chloroquine, which can pose a great challenge 
to the medical community.  Such drug resistance, although not always a life threatening 
problem, can have devastating effects due to the lack of proper testing and the difficulty 
in receiving the correct medication in a timely manner.   
 
 As drug resistance develops to existing drugs, new ones need to be introduced. 
For Plasmodium falciparum use of two or more drugs with different modes of action in 
combination is now recommended to provide adequate cure rate and delay 
development of resistance (White, 2004). 
  
Cloroquine-Resistant Malaria (CRM) in Haiti 
 Drug resistance has been well documented in two species of malarial parasites; 
Plasmodium falciparum and Plasmodium vivax. Of greatest concern are the rapid 
developments in the resistance of Plasmodium falciparum to the commonly used 
chemoprophylactic agent, chloroquine-phosphate. This species, which is capable of 
producing life-threatening disease, has shown various levels of resistance in different 
parts of the world.  Despite evidence of failing chloroquine efficacy, little work has 
assessed the problem or explored alternative therapies. 
 
 Since no therapies either on the market or under development are totally 
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protective against malaria, there is the possibility of resistance developing to any given 
therapy that is developed. This is a serious concern, as the rate at which new drugs are 
produced by no means matches the rate of the development of resistance. In addition, 
the most newly developed therapeutics tends to be the most expensive and is required 
in the largest quantities by some of the poorest areas of the world (Baird, ).  
 
 Chloroquine was the main malaria therapy worldwide from the 1940s until the 
1990s. Following the emergence of chloroquine-resistant Plasmodium falciparum, most 
African countries, where CRM is widespread, have discontinued the use of chloroquine 
and now promote artemisinin-based combination therapy as the first-line treatment 
(CDC, 2011).  Antimalarial drug resistance is a major obstacle to the control of malaria 
in endemic countries. For example, in 2012, Bangladesh reported an estimated 29,522 
malaria episodes, of which 94% were reported as being caused by Plasmodium 
falciparum (van den Broek, 2004). This is alarming due to the many published studies 
that indicate that P. falciparum shows varying levels of resistance to chloroquine, 
mefloquine and sulfadoxine-pyrimethamine.  
 
 Haiti has been historically considered the outlier with no major reported 
outbreaks of CRM and has not needed to move to the artemisinin-based combination 
therapy.  This is in sharp contrast to places where the P. falciparum strain has been 
known to reside (CDC, 2010a).  However, a recent study that was performed that did 
show reported cases of CRM in Haiti (Londono, 2009).  In 2009, Berlin L. Londono et al 
was able to identify CRM cases in the low-lying Artibonite Valley area of Haiti.  Through 
passive and active surveillance, Londono was able to identify 79 P. falciparum 
infections out of 821 persons by using PCR for the P. falciparum gene.  Of these 79 
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cases, 4 were identified as being CRM for a percentage of 6%.  This was alarming to 
the medical community as it is the first cases of reported CRM in Haiti (2009).   
 
 In 2012, Ami Neuberger et al performed a follow-up study to Londono’s work to 
look for CRM in Haiti (2012).  This study looked at 49 patients with falciparum malaria in 
order to detect CRM.  The results of this study did not detect CRM.  However, this study 
had many flaws.  First, the study was performed in Leogane, a town of 200,000 
residents, located 30km west of Port-au-Prince.  The Londono study was performed in 
Artibonite Valley which 100km north of Port-au-Prince.  This change in location could 
show that there is a varying of disease by geographical region and not a true lack of 
disease.  Also, the small sample size of only 49 patients could have led to a missing of 
disease.  Finally, the way the disease was detected was through follow-up of patients 
after the falciparum malaria after treatment with chloroquine for 1 month.  This short 
follow-up or incomplete follow-up time may not have been adequate to detect true CRM 
(2012).  Based on these two studies, continued surveillance is needed in Haiti to rule 
out and prepare for the emergence of CRM. 
  
Factors Effecting Malaria Control 
 Many factors combine together to affect the health of individuals and 
communities. These factors, known as determinants of health, play a major role in 
determining whether a person is healthy or not. According to the World Health 
Organization, there are seven determinants of health.  These determinants are: 
1. Income and social status/poverty 
2. Education  
3. Physical environment  
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4. Social support  
5. Genetics  
6.  Health services 
7. Gender (WHO, 2013a) 
  
 While all these seven play a major role in the health of the Haitian people, two of 
these determinants seem to play the largest and most major roles in the current malaria 
problem; income and social status/poverty and health services.  Ultimately these 
determinants will determine the recommendations for malarial control.   
 
Income and Social Status/Poverty 
 Haiti has occupied the unenviable position of being the poorest nation in the 
Western Hemisphere for decades. Income per capita ranges from US $400 to US $560 
with 54% of Haitians living on less than US $1 a day and 78% living on less than US $2 
a day. Rural Haitians income per capita is even less; coming in at US $100 (UNICEF, 
2013).  The effect of living in poverty ultimately has a dramatic impact on health, putting 
developing communities at risk through the increased sharing of limited space, lack of 
education on health issues, lack of healthcare, lack of housing, inadequate food and 
clean water, and exposure to vectors that can spread disease.   
  
Health Services 
 In terms of health care spending, Haiti ranks last in the western hemisphere 
(Alfred, 2012). Economic instability has limited any growth in this area. Per capita, Haiti 
spends about US$83 annually on health care. Most rural areas have no access to 
health care, making residents susceptible to otherwise treatable diseases.  Only one-
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fourth of births are attended by a skilled health professional (US Library of Congress, 
2006).  
 
 Obtaining accurate numbers of currently open and functioning Haitian hospitals is 
extremely difficult.  However, current estimates show that there are between 30-40 
hospitals currently open nationwide to take care of the needs of 10.17 million people.  
The average rate of physicians per 100,000 population is also difficult to determine.  
However, the United Nations reports this number as 25 physicians per 100,000 
population (Henry J Kaiser Foundation, 2013) (United Nations, 2008).  While this is not 
the lowest in the world, it is considerably low.   
 
 Furthermore, of the few hospitals that do exist, these hospitals are unfortunately 
inadequate in order to take care of the needs of the Haitian people due to the sheer 
volume of patients.  The Haitian hospitals lack the sufficient medical staff, support staff, 
training, equipment and treatment. The largest public hospital, Haiti’s University and 
Educational Hospital (HUEH), was partially damaged in the earthquake with 150 nursing 
students killed and two-thirds of the buildings destroyed (Partners in Health, 2010).  
  
Recommendations 
 Diverse opinions have emerged about the best way to scale up malaria 
interventions. Three controversies/questions seem most important and were used when 
considering the following proposed recommendations.  These controversies/questions 
are:  
(1) Should the recommendation focus on a broader target of febrile illness, or be 
specific to malaria only?  
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(2) Should the recommendation feature a single intervention or be targeted at a 
much broader situation or an entire determinant of health?  
(3) Should the recommendation have a preference for a single delivery method or 
focus on multiple methods? (Gaumer, 2013) 
 
1. Creating sustainable health care opportunities on the local level 
  Provisions essential to the control of malaria include the delivery of fast primary 
care where health care staff is well trained and supported with the necessary supplies 
for efficient treatment.  However, in Haiti, this is a major issue due to the lack of medical 
staff.  Due to this, providing adequate health care job opportunities and career 
development to the long-term success of revamping the local Haitian health care 
system is difficult. Currently, there is insufficient health care staff in Haiti to help provide 
medical care at the local level. Reasons for this include: lack of job opportunities 
(hospitals), need to gain advanced training outside of Haiti, and poor wages in the 
health care industry (Haar, 2012).  These are the same reasons why local health care 
professionals choose to migrate outside of Haiti. Health professionals who leave for 
training but return may have the needed skills to help, but do not have the needed 
infrastructure and support to practice their trade.  Therefore, those that do receive 
training tend to leave for other opportunities in other locations rather than staying to help 
their local neighbors.   
 
 There is also the problem of physicians/health care workers from high-income 
countries coming to Haiti.  Although these physicians/health care workers try to help 
make a difference, long-term damage can occur to what little health care infrastructure 
does exist in Haiti.   
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 When high-income physicians come to Haiti to help see patients, the Haitians 
lose respect for the local Haitian trained health care staff, looking down on them as 
inferior.  As this begins to happen, no matter how well meaning or energetic, the brief 
tenure of the high-income country doctors do not create a system that helps from within.  
 
 Acknowledging this issue is therefore an actual part to the solution.  Although 
high-income physicians feel the need to travel to Haiti to provide medical care, a strong 
recommendation should be that these physicians focus their resources on teaching and 
training the local Haitian health care providers rather than treating and healing Haitian 
patients.  This will require cooperation and coordination with the existing infrastructure.   
 
 Because local Haitian providers are the backbone of the health-care sector, it is 
vital for all actors to create an active dialogue on this issue. There will certainly be 
difficulty in accessing and motivating private providers to tackle the management of 
impoverished communities that may not be able to pay sufficiently, but creative 
solutions such as subsidizing care for poor people within the private system have been 
utilized in some situations and may prove useful in Haiti. As Haiti rebuilds over the next 
several years, local, governmental and international organizations must leverage the 
enormous potential of the providers already present to more equitably distribute work 
and create a more effective health-care infrastructure.   
 
2. Early recognition of malaria utilizing malaria RDTs to minimize CRM impact 
 A more practical approach to helping control and eliminate CRM is through 
providing and utilizing malaria RDTs.  For many years the only malarial test approved in 
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the Haitian national policy for the diagnosis and management of malaria was 
microscopy.  However, the use of microscopy often was limited by lack of equipment or 
trained personnel. In contrast, malaria RDTs require less equipment or training to use. 
RDTs were not incorporated into the MSPP malaria control strategy because of 
concerns that these newer tools, when compared with microscopy, would not be 
sufficiently sensitive and would be difficult to sustain in some settings in Haiti. However, 
after the earthquake, the acute need for clinical services and malaria diagnostics, and 
the presence of international nongovernmental organizations assisting with the 
response, MSPP allowed the temporary use of RDTs.  
 
 Following the temporary usage of RDT’s, the MSPP and CDC compared the 
performance of expert microscopy with the performance of two brands of RDTs 
introduced temporarily in Haiti for malaria diagnosis. Four health facilities were included 
in the assessment.  
 
 Based on these findings the MSPP adopted the use of RDTs as part of the 
national strategy at the following health facilities: 
• Health centers and clinics without microscopy capacity; and 
• Departmental hospitals, community referral hospitals, and specialty hospitals 
during laboratory off-hours or if microscopy is not available (CDC, 2010b). 
 
 RDTs can increase the early recognition of malaria when the availability of 
laboratory-based diagnosis is not available.   This therefore will help to improve the 
overall management of febrile patients in malaria endemic areas.  
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 This application has been studied and used throughout the world in situations 
similar to Haiti.  For example, in preparation to scale-up the usage of RDTs in health 
facilities in Malawi, an evaluation of four RDTs was conducted to help guide national-
level decision-making was conducted.  Combined with other published data and global 
recommendations, the results of this evaluation have subsequently been used to 
increase national uptake.  Effectiveness was measured as the number and proportion of 
patients correctly diagnosed and treated. Incremental Cost-Effectiveness Ratios 
(ICERs) were estimated from the societal perspective.  In this particular study, RDT 
usage was most cost-effective with lowest ICER US$5.0 compared to microscopy 
US$9.61 per case correctly diagnosed and treated. In the high transmission setting, 
ICER was US$4.38 for RDT and US$12.98 for microscopy. The corresponding ICERs in 
the low transmission setting were US$5.85 and US$7.63 respectively (Lauer, 2010). 
 
3. Utilize public sources to distribute malarial medicines when external sources 
are inadequate 
 Ensuring that the poor and vulnerable populations benefit from malaria control 
interventions remains a challenge for all malaria endemic countries. Providing long 
term, sustainable health care programs that seek ethical partnerships with community 
leaders, while introducing a consensus community engagement can build relationships 
that will help to prioritize the health needs in local cities/villages. This community 
engagement model can be used to educate villages on the importance to recognize 
malaria as it occurs.  Creating strategies for preventing infections have shown to have 
substantial effect on the potential rate of development of resistance. 
 
 17 
 Until recently, ownership and use of insecticides treated nets (ITNs) in most 
countries was low and inequitable.  However, coverage has increased in countries 
where free ITN distribution is integrated into mass vaccination campaigns. In Kenya, 
free ITNs were distributed to children aged below five years in 2006 through two mass 
campaigns. High and equitable coverage were reported after the campaigns in some 
districts, although national level coverage remained low, suggesting that understanding 
barriers to access remains important (Chuma, 2010). 
 
 Although there may not be an ideal situation to bring in outside public sources, 
an approach, such as the one seen in Kenya, can serve as a potential recommendation 
for Haiti.  Further, this type of approach seems to make the most sense in situations 
where dire needs are not being met, as is currently seen in Haiti.  It is because of this 
reason that there should be a recommendation for using various public methods of 
obtaining outside resources.   
 
 Another more widely used method, which has been recently seen in Haiti, has 
been with the use of public, Non-Governmental Organizations (NGOs).  One medical 
benefit that NGOs have provided regarding malaria has been through their ability to 
purchase malarial drugs through the open market from sources not officially related to 
the Haitian health care industry.  
 
 This such public method has been utilized in other parts of the world and in Haiti, 
since the earthquake.  Although the evidence shows that there is no short cut to 
investing in training and supervision of providers, or in treating malaria through Haitian 
health care workers, there have been recent publications that have shown that the 
 18 
public sector has made progress in prevention and treatment in many countries (Kamal-
Yanni, 2012).  These studies have highlighted that the public NGO outlets face 
challenges in delivering their services, however, their role should be recognized and 
expanded in a limited role.   
 
Conclusion 
 As discussed, malaria is a major public health problem and therefore it needs the 
adequate focus of both public health officials and health care providers in order to 
reduce its impact.  In order to do this, recommendations must be formed and steps must 
be taken.   If these actions are not taken, then the very real possibility of a CRM 
outbreak can occur with the potential to have devastating effects. 
. 
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